Micronized fenofibrate: Phase IV; marketed as adjunct to treat primary hypercholesterolemia

Researchers reported in The Lancet results from an international, placebo-controlled post-marketing study

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE